U.S. Markets closed

Satsuma Pharmaceuticals, Inc. (STSA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.34+0.31 (+6.16%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.03
Open5.04
Bid5.23 x 1000
Ask5.44 x 800
Day's Range4.98 - 5.64
52 Week Range3.50 - 36.10
Volume511,449
Avg. Volume348,511
Market Cap93.035M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-11.20
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
  • Benzinga

    5 Value Stocks In The Healthcare Sector

    What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching: 1. Innoviva (NASDAQ:INVA) - P/E: 6.35 2. Satsuma Pharmaceuticals (NASDAQ:STSA) - P/E: 2.4 3. Ocugen (NASDAQ:OCGN) - P/E: 0.48 4. Biogen (NASDAQ:BIIB) - P/E: 8.08 5. Global Cord Blood (NYSE:CO) - P/E: 5.83Most recently, Innoviva reported earnings per share at 0.26, whereas in Q2 earnings per share sat at 0.69. Innoviva does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Satsuma Pharmaceuticals experienced a decrease in earnings per share, which was -0.65 in Q2 and is now -0.69. Satsuma Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Ocugen's earnings per share for Q3 sits at -0.02, whereas in Q2, they were at -0.19. Ocugen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Biogen reported earnings per share at 8.84, whereas in Q2 earnings per share sat at 10.26. Biogen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.This quarter, Global Cord Blood experienced an increase in earnings per share, which was 0.15 in Q1 and is now 0.16. Global Cord Blood does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.See more from Benzinga * Click here for options trades from Benzinga * Overview Of Value Stocks In The Real Estate Sector * Stocks That Hit 52-Week Lows On Monday(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is STSA A Good Stock To Buy Now?
    Insider Monkey

    Is STSA A Good Stock To Buy Now?

    Is Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

  • Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
    GlobeNewswire

    Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the Evercore ISI 3rd Annual HealthCONx Conference. Please see additional details below:Dates:Tuesday – Thursday, December 1st-3rd 2020 Format:One-on-one meetings with Satsuma Management Location:Virtual Meetings About Satsuma Pharmaceuticals and STS101 Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming these shortcomings.Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.INVESTOR AND CORPORATE CONTACTS:Corey Davis, PhD LifeSci Advisors, LLC cdavis@lifesciadvisors.comTom O’Neil, Chief Financial Officer Satsuma Pharmaceuticals, Inc. tom@satsumarx.com